FDA Grants Orphan Drug Status to AbbVie’s Therapy for Pediatric Crohn’s Disease

FDA Grants Orphan Drug Status to AbbVie’s Therapy for Pediatric Crohn’s Disease
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to AbbVie’s investigational drug risankizumab for the treatment of pediatric patients with Crohn’s disease. Risankizumab (ABBV-066) selectively blocks IL-23, a key protein involved in inflammatory processes that have been linked to a number of chronic immune-mediated diseases. Risankizumab is part of a collaboration

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *